Form 4: Entrada Therapeutics CEO Dipal Doshi Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Entrada Therapeutics CEO Dipal Doshi sold shares of common stock on July 12 and July 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Dipal Doshi, CEO of Entrada Therapeutics, sold 300 shares of common stock on July 12, 2024, at a price of $18 per share.
- On July 15, 2024, Doshi sold an additional 1,600 shares at a weighted average price of $17.8108.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on May 15, 2023.
- Following these transactions, Doshi directly owns 334,475 shares of Entrada Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports stock sales under a pre-existing trading plan, which is a common practice.
Industry Context
Sales by company executives are a common occurrence and are often pre-planned through Rule 10b5-1 trading plans to avoid accusations of insider trading. The market typically views these sales in the context of the executive's overall holdings and the company's performance.
Stakeholder Impact
- The stock sales may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
- The sales do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| May 15, 2023 | Date of adoption of Rule 10b5-1 trading plan |
| July 12, 2024 | Date of first stock sale (300 shares at $18) |
| July 15, 2024 | Date of second stock sale (1,600 shares at weighted average price of $17.8108) |
| July 16, 2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.